Company Description
Metagenomi, Inc., a genetic medicines company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States.
The company's genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems, such as prime editing systems and clustered regularly interspaced short palindromic repeat-associated transposases.
It has a development, option, and license agreement with Affini-T Therapeutics, Inc. to develop and commercialize gene edited T-cell receptor-based therapeutic products in the field of treatment, prevention, or diagnosis of human cancer; and a collaboration and license agreement with Ionis Pharmaceuticals, Inc. to research, develop, and commercialize investigational medicines using genome editing technologies.
The company was incorporated in 2016 and is based in Emeryville, California.
| Country | United States |
| Founded | 2018 |
| IPO Date | Feb 9, 2024 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 237 |
| CEO | Dr. Brian Charles Thomas Ph.D. |
Contact Details
Address: 5959 Horton Street, 7th Floor Emeryville, California 94608 United States | |
| Phone | (510) 871-4880 |
| Website | metagenomi.co |
Stock Details
| Ticker Symbol | MGX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $15.00 |
| CIK Code | 0001785279 |
| Employer ID | 81-3909017 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Brian Charles Thomas Ph.D. | Co-Founder, Chief Executive Officer and Chairman of the Board |
| Dr. Jian Irish M.B.A., Ph.D. | President, Chief Operating Officer and Director |
| Dr. Sarah B. Noonberg M.D., Ph.D. | Chief Medical Officer |
| Dr. Jak Knowles M.D. | Co-Founder and Member of Scientific Advisory Board |
| Pamela M. Wapnick M.B.A. | Chief Financial Officer |
| Dr. Luis G. Borges Ph.D. | Chief Scientific Officer |
| Matthew L. Wein J.D. | Vice President of Corporate Legal, Compliance and Corporate Secretary |
| Dr. Alan Brooks Ph.D. | Senior Vice President of Preclinical |
| Dr. Christopher Brown | Head of Discovery |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 14, 2024 | 8-K | Current Report |
| May 14, 2024 | 10-Q | Quarterly Report |
| May 10, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| May 1, 2024 | 8-K | Current Report |
| Mar 27, 2024 | 8-K | Current Report |
| Mar 27, 2024 | 10-K | Annual Report |
| Feb 13, 2024 | 8-K | Current Report |
| Feb 12, 2024 | 424B4 | Prospectus |
| Feb 9, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
| Feb 8, 2024 | EFFECT | Notice of Effectiveness |